Sun Pharma And Pharmazz Inc Join Forces To Introduce Sovateltide Tyvalzi In India

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Sun Pharma and Pharmazz Inc. join forces to introduce Sovateltide (Tyvalzi™) in India

ri-calendar-2-lineSep 14, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Sun Pharmaceutical Industries Limited has entered into a licensing agreement with U.S.-based biopharmaceutical company Pharmazz Inc. to bring Sovateltide, a groundbreaking drug for the treatment of acute cerebral ischemic stroke, to India. Sovateltide, to be marketed in India as Tyvalzi™ (Sovateltide), is the first-of-its-kind medication that can be administered up to 24 hours after the onset of stroke symptoms.

 

Under the agreement, Sun Pharma's subsidiary gains the rights to market Tyvalzi™ in India. Pharmazz will receive upfront payments, milestone payments, and royalties as part of the collaboration.
 

Kirti Ganorkar, CEO of Sun Pharma's India Business, is enthusiastic about Tyvalzi™'s potential: “The Phase 3 clinical trial for Tyvalzi™ demonstrated statistically and clinically significant improvements in neurological outcomes for ischemic stroke patients. It significantly extends the treatment window to 24 hours, compared to the current 4-5 hour limit for existing treatments.”
 

Dr. B. S. Paul, a prominent neuro-physician, highlighted the urgent need for new stroke treatments and emphasized Sovateltide's promise as it can be administered up to 24 hours after a stroke. Dr. Prof. Anil Gulati, the inventor of Sovateltide and CEO of Pharmazz, believes this partnership with Sun Pharma is a significant milestone in addressing India's stroke healthcare challenge.

 

Stroke is a major concern in India, with over a million estimated cases and ranking as the fourth leading cause of death and fifth leading cause of disability. This collaboration aims to provide effective stroke treatments, offering hope and improvement for stroke patients in India.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions